




ABSORBANCE RATIO SPECTROPHOTOMETRIC METHOD FOR THE SIMULTANEOUS 
ESTIMATION OF DEXAMETHASONE SODIUM PHOSPHATE AND ATROPINE SULPHATE IN EYE 
DROP 
HIRAL M. POKIYA1*, HASUMATI A. RAJ1, VINEET C. JAIN1 
1Shree Dhanvantary College of pharmacy, Kim, Surat, Gujarat, India. Email: pokiyahiral@yahoo.in 
Received:26 April 2014, Revised and Accepted:10 May 2014 
ABSTRACT 
A simple, sensitive, rapid, accurate, precise Absorbance Ratio Method was developed for the simultaneous determination of Dexamethasone Sodium 
Phosphate and Atropine Sulphate in combined dosage form. Absorbance ratio method uses the ratio of absorbance at two selected wavelengths, one 
which is an iso absorptive point and other being the λmax of one of the two components. Dexamethasone Sodium Phosphate and Atropine Sulphate 
show an iso absorptive point at 228.60 nm in methanol. The second wavelength used is 239.60 nm, which is the λmax of Dexamethasone Sodium 
Phosphate in methanol. The linearity was obtained in the concentration range of 20-60 μg/ml for Atropine Sulphate (r2=0.9991) and 2-6 μg/ml for 
Dexamethasone Sodium Phosphate(r2=0.9994).LOD is 0.063 and 3.01 μg/ml for Dexamethasone Sodium Phosphate and Atropine Sulphate 
respectively.LOQ is 0.19 and 9.12 μg/ml for Dexamethasone Sodium Phosphate and Atropine Sulphate respectively. The concentrat ions of the drugs 
were determined by using ratio of absorbance at iso absorptive point and at the λmax of Dexamethasone Sodium Phosphate. The method was 
successfully applied to pharmaceutical dosage form because no interference from the excipients was found. The results of analysis have been 
validated.  
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INTRODUCTION 
Atropine is a naturally occuring tropen alkaloid and basic in nature. 
It is an anticholinergic or parasympatholytic drug. It inhibits the 
muscarinic actions of acetylcholine [1].Atropine Sulphate is 
chemically [Bis[(1R,3R,5S)-8-methyl-8-azabicyclo [3,2,1]oct-3-
yl(2RS)-3-hydroxy-2-phenylpropanoate] sulphate] and in Indian, 
British, United States, European Pharmacopoeia[2-5]. In literature, 
several analytical methods such as Uv-Visible spectroscopy [6-8], 
HPLC [9-15] and UPLC [16] have been reported for the determination of 
Atropine Sulphate single and in combination with other drugs in its 
pharmaceutical formulation. 
Dexamethasone Sodium Phosphate is a glucocorticoid and 
suppresses normal immune response [1]. Chemically 9-Fluoro-11β, 
17-dihydroxy-16α-methyl-3, 20-dioxopregna-1,4-dien-21-yl 
disodium phosphate and Dexamethasone Sodium Phosphate official 
in Indian,British, European and United States Pharmacopoeia[2-5]. In 
literature, several analytical methods such as Uv-Visible 
spectroscopy [17-22], polarographic [23], HPLC [24-36] and HPTLC [37-38] 
have been reported for the determination of Dexamethasone Sodium 
Phosphate single and in combination with other drugs in its 
pharmaceutical formulation. 
The combination of these two drugs is not official in any 
pharmacopoeia; hence no official method is available for the 
simultaneous estimation of Dexamethasone Sodium Phosphate and 
Atropine Sulphate in their combined dosage forms. Literature survey 
does not reveal any simple spectrophotometric method for the 
simultaneous determination of Atropine Sulphate and 
Dexamethasone Sodium Phosphate in combined dosage form. 
Therefore, an objective of this work is to develop 
spectrophotometric method based on Q-absorbance ratio 
spectrophotometric method for the simultaneous determination of 
both these drugs in their combined dosage form. The second 
objective is to validate the method as per the ICH guidelines. 




      
Fig.1: Structure of Atropine Sulphate 
 
Fig.2: Structure of Dexamethasone Sodium Phosphate  
MATERIALS & METHODS 
Materials 
Spectroscopic Analysis was carried out on a UV/VISIBLE 2450 
(Shimadzu) double beam UV-Visible spectrophotometer with 
software of UV Probe version 2.34. The zero order absorption 
spectra were recorded over the wavelength range of 200-400 nm, 
against solvent blank, in quartz cuvettes with 1 cm diameter. A Semi 
micro analytical balance (Sartorius CD2250, Germany) was used for 
weighing purpose. Atropine Sulphate obtained as gift samples from 
Yarrow Chem. Products Mumbai-India and Dexamethasone Sodium 
Phosphate from Enzal Chemicals (I) Ltd. Panoli.The commercial 
fixed dose combination product was procured from the local market.  
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Preparation of Standard Solutions 
A 10 mg of standard Dexamethasone Sodium Phosphate and 
Atropine Sulphate were weighed and transferred to 100 ml separate 
volumetric flasks and dissolved in methanol. The flasks were shaken 
and volumes were made up to mark with methanol to give a solution 
containing 100μg/ml each of Dexamethasone Sodium Phosphate and 
Atropine Sulphate. 
Methodology 
Absorbance ratio method uses the ratio of absorbance at two 
selected wavelengths, one which is an iso absorptive point and other 
being the λmax of one of the two components. From the overlay 
spectra of two drugs, it is evident that DSP and ATR show an iso 
absorptive point at 228.60 nm. The second wavelength used is 
239.60 nm, which is the λmax of DSP (Figure 3). Working standard 
solutions having concentration 2,3,4,5 and 6 μg/ml for DSP and 
20,30,40,50,and 60 μg/ml for ATR were prepared in methanol and 
the absorbance at 228.60 nm (iso absorptive point) and 239.60 nm 
(λmax of DSP) were measured and absorptivity coefficients were 
calculated using calibration curve. 
The concentration of two drugs in the mixture can be calculated 
using following equations. 
CX = [(QM – QY) / (QX -QY)] × A1/ax1 __________ (1) 
CY = [(QM – QX) / (QY -QX)] × A1/ay1 __________ (2) 
Where, A1 and A2 are absorbance of mixture at 228.60 nm and 
239.60 nm; ax1 and ay1 are absorptivities of DSP and ATR at 228.60 
nm; ax2 and ay2 are absorptivities of DSP and ATR respectively at 
239.60 nm; QM = A2 / A1, QX = ax2 / ax1 and QY = ay2 / ay1. 
 
Figure 3: Overlain absorption spectra of DSP (239.60 nm) and 
ATR (257.60 nm) showing iso absorptive point (228.60 nm) in 
methanol. 
VALIDATION  
The proposed method was validated according to the International 
Conference on Harmonization (ICH) guidelines. 
Linearity (Calibration Curve) 
The calibration curves were plotted over a concentration range of 2-
6 μg/ml for DSP and 20-60 μg/ml ATR. Appropriate aliquots from 
the standard stock solutions of DSP and ATR were used to prepare 
two different sets of dilutions: Series A, and B as follows. Series A 
consisted of different concentration of DSP (2-6 μg/ml). Aliquot from 
the stock solution of DSP (100 μg/ml) was pipette out in to a series 
of 10 ml volumetric flask and diluted with methanol to get final 
concentration in range of 2-6 μg/ml (0.2, 0.3, 0.4, 0.5 and 0.6 ml). 
Series B consisted of varying concentrations of ATR (20-60 μg/ml). 
Appropriate volume of the stock solution of ATR (100 μg/ml) was 
transferred into a series of 10 ml volumetric flask and the volume 
was adjusted to the mark with methanol to get final concentration in 
range of 20-60 μg/ml (2.0,3.0,4.0,5.0 and 6.0 ml). The absorbances of 
solution were then measured at 239.60nm and 228.60nm.(Table 1) 
The calibration curves were constructed by plotting absorbance 
versus concentration and the regression equations were 
calculated.(Figure 4 and 5) 



























































y = 0.03732x + 0.01075 for DSP at 239.60nm___________ (3) 
y = 0.00323+0.01320 for ATR at 228.60nm______________ (4) 
 
 
Fig.4: Calibration graph of Dexamethasone Sodium Phosphate 
at 239.60 nm 
 
 
Fig.5: Calibration graph of Atropine Sulphate at 228.60 nm 
Precision (Reproducibility) 
The intraday and interday precision of the proposed method was 
determined by analyzing the corresponding responses 3 times on 
the same day and on 3 different days over a period of 1 week for 3 
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different concentrations of standard solutions of DSP and ATR (2,4,6 
μg/ml for DSP and 20, 40, 60μg/ml for ATR). The result was 
reported in terms of relative standard deviation (Table no 2 and 3) 













2 20 0.0875±0.00030 0.34 0.1425±0.00035 0.24 
4 40 0.1677±0.00055 0.33 0.2457±0.00070 0.28 
6 60 0.2524±0.00056 0.22 0.3683±0.00085 0.23 













2 20 0.0868±0.00035 0.40 0.1420±0.00075 0.52 
4 40 0.1682±0.00050 0.29 0.2472±0.00090 0.36 
6 60 0.2522±0.00065 0.26 0.3680±0.00075 0.20 
Accuracy (Recovery Study) 
The accuracy of the method was determined by calculating the 
recoveries of DSP and ATR by the standard addition method. Known  
amounts of standard solutions of DSP and ATR were at added at 80, 
100 and 120 % level to pre quantified sample solutions of DSP and 
ATR (2μg/ml for DSP and 20μg/ml for ATR). The amounts of DSP 
and ATR were estimated by applying obtained values to the 
respective regression line equations.Data given in table 4 and 5.  
LOD and LOQ 
The limit of detection (LOD) and the limit of quantification (LOQ) of 
the drug were derived by calculating the signal-to-noise ratio (S/N, 
i.e., 3.3 for LOD and 10 for LOQ) using the following equations 
designated by International Conference on Harmonization (ICH) 
guidelines. 
LOD = 3.3 × σ/S 
LOQ = 10 × σ/S 
Where, σ = the standard deviation of the response and 
S = slope of the calibration curve. 
Robustness and Ruggedness 
Different Instrument and different stock solution was used for 
Robustness and Ruggedness No significant changes in the spectrums 
were observed, proving that the developed method is rugged and 
robust.(Given in table 6) 
 
Table 4: Recovery data of DSP *(n=3) 
Conc. 
of DSP from formulation 
(µg/ml) 
Amount of Std.DSP 
added (µg/ml) 
Total amount of 
DSP 
(µg/ml) 
Total amount of DSP 
found (µg/ml)* 





2 1.6 3.6 3.58±0.016 99.67 0.45 
2 2 4 4.02±0.007 100.61 0.18 
2 2.4 4.4 4.39±0.015 99.83 0.34 
Table 5: Recovery data of ATR *(n=3) 
Conc. 





Total amount of 
ATR 
(µg/ml) 
Total amount of ATR 
found (µg/ml)* 





20 16 36 36.04±0.147 100.11 0.46 
20 20 40 39.88±0.056 99.71 0.33 
20 24 44 43.95±0.070 99.89 0.18 
 
Table 6: Robustness and Ruggedness data of DSP and ATR *(n=3) 
Conc. (ppm) Dexamethasone Sodium Phosphate (Mean abs. ±% RSD) 
Instrument 1 Instrument 2 Stoke – 1* Stoke – 2* 
2 0.0867±0.59 0.0877±0.45 0.0878±0.28 0.0877±0.52 
3 0.1278±0.29 0.1274±0.43 0.1278±0.35 0.1277±0.43 
4 0.1662±0.30 0.1667±0.24 0.1657±0.36 0.1652±0.46 
Atropine Sulphate (Mean abs. ±% RSD) 
20 0.1413±0.39 0.1416±0.52 0.1426±0.42 0.1415±0.45 
30 0.1969±0.40 0.1967±0.38 0.1970±0.38 0.1977±0.30 
40 0.2446±0.22 0.2448±0.22 0.2442±0.26 0.2436±0.17 
 
Assay procedure 
From the formulation 1ml transferred in 100 ml volumetric flask 
and made up to the mark with the Methanol. Stock solution 
contained 10μg/ml DSP and 100μg/ml ATR and from that pipette 
out 2 ml and transferred in 10 ml volumetric flask and made up to 
the mark with the Methanol. The absorbance of the sample solution 
i.e. A1 and A2 were recorded at 228.60 nm  (iso absorptive point) and 
239.60 nm (λmax of DSP) respectively. (Given in table 7) 
RESULTS AND DISCUSSION 
The overlain UV absorption spectra of DSP (239.60 nm) and ATR 
(257.60 nm) showing iso absorptive point (228.60 nm) in methanol 
is shown in Figure 3. Accuracy was determined by calculating the 
recovery and the mean was determined (Table 4 and 5). The method  
 
was successfully used to determine the amounts of DSP and ATR 
present in dosage forms. The results obtained were in good 
agreement with the corresponding labeled amount (Table 
7).Precision was calculated as intra and inter day variations (% RSD) 
for both the drugs. Summary of validation parameters for method is 
given in Table 8. By observing the validation parameters, the method  
was found to be simple, sensitive, accurate and precise. Hence the 
method can be employed for the routine analysis of these two drugs 
in combined dosage form. 
CONCLUSION 
The proposed spectrophotometric method was found to be simple, 
sensitive, accurate and precise for determination of DSP and ATR in 
dosage form. The method utilizes easily available and cheap solvent 
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for analysis of DSP and ATR hence the method was also economic for 
estimation of DSP and ATR from dosage form. % recoveries greater 
than 99 % shows that method is free from the interference of 
excipients used in the formulation 
Table7: Analysis data of formulation *(n=3) 
Sr. No Drug Formulation 
(μg/ml) 
% Assay ± SD* 
1 DSP 2 100.12±0.80 
2 ATR 20 100.64±0.61 
  
Table 8: Regression Analysis Data and Summary of Validation 
Parameters for DSP and ATR by Absorbance Ratio Method 
PARAMETERS  Absorption Ratio Method 
DSP ATR 
Concentration range(µg/ml) 2-6 20-60 
Regression equation y= 0.03732x + 
0.01075 
y = 0.00323x + 
0.01320 
Correlation Coefficient(r2) 0.9994 0.9991 
Accuracy(%Recovery) (n=3) 100.04 99.90 
Intra-day Precision (%RSD) 
(n=3) 
0.22-0.34 0.23-0.28 
Inter-day precision (%RSD) 
(n=3) 
0.26-0.40 0.20-0.52 
LOD(µg/ml) 0.063 3.01 
LOQ(µg/ml) 0.19 9.12 
Ruggedness and Robustness 0.24-0.59 0.17-0.52 
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